Physician profile
Mark A Hernandez
NPI 1457416224
$3,027.04
in general payments reported to CMS, 2019-2025
29 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $241 · 2021: $563 · 2022: $313 · 2023: $354 · 2024: $240 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $424.84 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $404.57 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.93 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $258.83 | 2022-2025 | Zoryve, Livalo |
| Abbvie INC. | $231.57 | 2021-2024 | |
| Mylan Specialty L.P. | $230.15 | 2019-2024 | Yupelri |
| Pfizer INC. | $159.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $104.78 | 2019-2024 | Airsupra |
| Astellas Pharma US INC | $96.25 | 2019-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $86.16 | 2021-2022 | |
| Lilly USA, LLC | $77.15 | 2019-2022 | |
| Horizon Therapeutics Plc | $62.21 | 2020-2021 | |
| Glaxosmithkline, LLC. | $60.22 | 2019-2024 | Trelegy Ellipta |
| Boston Scientific Corporation | $57.95 | 2019-2025 | Ranger, Watchman Flx |
| Exact Sciences Corporation | $56.46 | 2023 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.79 | 2019 | |
| Gilead Sciences, INC. | $49.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $41.88 | 2019-2021 | |
| Viatris Specialty LLC | $35.66 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $26.58 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $23.02 | 2025 | Rexulti |
| Grifols USA, LLC | $22.06 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.07 | 2019 | |
| Sanofi Pasteur INC. | $17.98 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.28 | 2024 | Voquezna |
| Allergan, INC. | $14.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.